Could a vaccine stop breast cancer before it starts?

NCT ID NCT06218303

First seen Mar 17, 2026 · Last updated May 09, 2026 · Updated 11 times

Summary

This study tests whether a vaccine targeting a protein called MUC1 can help prevent breast cancer in women with ductal carcinoma in situ (DCIS), a very early stage. About 50 women will either receive standard hormone therapy alone or hormone therapy plus the MUC1 vaccine before surgery. The goal is to see if the vaccine boosts the immune system to fight cancer cells and prevent recurrence.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DUCTAL CARCINOMA IN SITU are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • UPMC Magee Womens Hospital

    RECRUITING

    Pittsburgh, Pennsylvania, 15213, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.